替米沙坦治疗科恩 - 罗森塔尔糖尿病高血压大鼠：过氧化物酶体增殖物激活受体γ激动作用的益处
Telmisartan in the treatment of Cohen-Rosenthal Diabetic Hypertensive rats: the benefit of PPAR-gamma agonism.
作者信息
Younis Firas, Kariv Naam, Nachman Rachel, Zangen Sara, Rosenthal Talma
机构信息
Department of Physiology and Pharmacology, Hypertension Research Unit, Sackler School of Medicine, Tel Aviv University, aviv, Israel.
出版信息
Clin Exp Hypertens. 2007 Aug;29(6):419-26. doi: 10.1080/10641960701578444.
The antihypertensive and hypoglycemic effects of telmisartan, which has dual angiotensin II antagonist-PPAR-gamma agonist properties, was studied in Cohen-Rosenthal Diabetic Hypertensive rats (CRDH), a model in which hypertension, insulin resistance, and diabetes co-exist. CRDH, Cohen-diabetic rats (CDR), and SHR received telmisartan (3 mg/kg/day in drinking water) for five months. Telmisartan significantly lowered systolic and diastolic BP in SHR and CRDH, independent of body weight, and remained fairly constant in controls throughout the experiment. Blood glucose levels fell rapidly in the treated animals and remained steady in controls. Results indicate that telmisartan is a prototype of a new approach to treating coexisting diabetes and hypertension.
替米沙坦具有双重作用，既是血管紧张素II拮抗剂又是PPAR-γ激动剂，本研究在科恩 - 罗森塔尔糖尿病高血压大鼠（CRDH）中探究了其降压和降糖作用，CRDH是一种同时存在高血压、胰岛素抵抗和糖尿病的模型。CRDH大鼠、科恩糖尿病大鼠（CDR）和自发性高血压大鼠（SHR）饮用含替米沙坦（3毫克/千克/天）的水，持续五个月。替米沙坦显著降低了SHR和CRDH大鼠的收缩压和舒张压，与体重无关，且在整个实验过程中对照组血压保持相对稳定。治疗组动物的血糖水平迅速下降，而对照组保持稳定。结果表明，替米沙坦是治疗并存糖尿病和高血压新方法的一个范例。
Zotero 插件